A Phase 1/2 interventional study of IR Viloxazine and Placebo in Attention-Deficit/Hyperactivity Disorder (ADHD), sponsored by Supernus Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Supernus Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Attention Deficit Disorder with Hyperactivity · Supernus Pharmaceuticals, Inc..
Among the 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc., this one is the 18th largest by enrollment, is the only one that started in 2010, is the only one in phase 1/2, and was the 2nd registered.
1,818 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →1 of the 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:
Supernus Pharmaceuticals, Inc. · Sites in United States
Ages 48 mo–69 mo
By country, each count listing its studies:
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 12 · Phase 4 3
First in 2008; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 192 across the 22 interventional studies. Of the 19 that completed or were terminated, 16 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
Supernus Pharmaceuticals, Inc. is the lead sponsor of 64 studies on the registry; 6 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
1 of the studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02736656Phase 3Supernus Pharmaceuticals, Inc.Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This will be a randomized, double-blind, placebo-controlled, parallel group, safety and tolerability study in adults with ADHD. The target subjects are healthy male or female adults aged 18 to 64 years, inclusive, with a diagnosis of ADHD.
This will be a randomized, double-blind, multicenter, placebo-controlled, parallel group, safety and tolerability study in adults with ADHD. The target subjects are healthy male or female adults aged 18 to 64 years of age, inclusive, with a diagnosis of ADHD. Approximately 50 subjects will be enrolled at approximately 5 sites in the United States. Subjects will be randomized (1:1) to one of two treatment groups, immediate-release (IR) viloxazine or placebo. Primary objective is to determine the safety of IR viloxazine in adults with ADHD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A: immediate-release (IR) viloxazine capsules administered orally 3 times a day
Drug: IR Viloxazine
Treatment B: Placebo capsules administered orally 3 times a day
Drug: Placebo
One 50mg immediate-release viloxazine capsule administered orally 3 times a day (150mg total daily dose) for Week 1. Two 50mg immediate-release viloxazine capsules administered orally 3 times a day (300mg total daily dose) for Weeks 2 to 6.
Also known as: immediate-release viloxazine, SPN-812V immediate-release
Placebo capsules administered orally 3 times a day
Also known as: PBO
Incidence of Adverse Events During 6 Weeks of Treatment
The percent of subjects who took at least one dose of immediate-release viloxazine (Safety Population; N) and who reported at least one Adverse Event (n). The percent is calculated by dividing "the number of subjects who reported at least one Adverse Event (n)" by "the number of subjects in the Safety Population (N)" and multiplying the product by 100. The higher the percentage, the higher the incidence in the Safety Population
Time frame: Weeks 1-6
Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 6 (End of Study)
The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.
Time frame: Baseline and Week 6
Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 1
The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.
Time frame: Baseline and Week 1
Change in Global Clinical Impression-Improvement (CGI-I) Score From Baseline Global Clinical Impression-Severity of Illness (CGI-S) Score at Week 1, Week 2, Week 3, Week 4, Week 5, and Week 6
The Global Clinical Impression-Improvement (CGI-I) scale is a single item clinician-rated assessment of how much the subject's condition (symptoms) has improved, worsened, or has not changed relative to his/her baseline state prior to the beginning of treatment; it is rated on a 7-point scale from 1 to 7, where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. The Clinical Global Impression-Severity of Illness (CGI-S) score is a single item clinician-rated assessment of the severity of subject's condition (symptoms) in relation to the clinician's total experience with patients with ADHD; it is rated on a 7-point scale with 1=Normal, not at all ill, 2=Borderline Ill, 3=Mildly Ill, 4=Moderately Ill, 5=Markedly Ill, 6=Severely Ill, 7=Among the most extremely ill patients. CGI-I scores at post-baseline visits were subtracted from CGI-S score at baseline; a change from baseline score \<0 represent better outcome.
Time frame: Weeks 1, 2, 3, 4, 5, and 6
Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 2, Week 3, Week 4, and Week 5
The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.
Time frame: Baseline and Weeks 2, 3, 4, and 5
Change From Baseline in the Self-rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 6
The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.
Time frame: Baseline and Week 6
Global Clinical Impression-Improvement (CGI-I) Score at Week 1, Week 2, Week 3, Week 4, Week 5, and Week 6
The Global Clinical Impression-Improvement (CGI-I) scale is a single item clinician-rated assessment of how much the subject's condition (symptoms) has improved, worsened, or has not changed relative to his/her baseline state prior to the beginning of treatment; it is rated on a 7-point scale from 1 to 7, where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. A CGI-I score \<4 represents a better outcome.
Time frame: Weeks 1, 2, 3, 4, 5, and 6
| Milestone | IR Viloxazine | Placebo |
|---|---|---|
| Started | 26 | 26 |
| Dosed | 26 | 25 |
| Completed | 24 | 24 |
| Not completed | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
The percent of subjects who took at least one dose of immediate-release viloxazine (Safety Population; N) and who reported at least one Adverse Event (n). The percent is calculated by dividing "the number of subjects who reported at least one Adverse Event (n)" by "the number of subjects in the Safety Population (N)" and multiplying the product by 100. The higher the percentage, the higher the incidence in the Safety Population
| percentage of subjects | IR Viloxazine | Placebo |
|---|---|---|
| Incidence of Adverse Events During 6 Weeks of Treatment | 88.5 | 72.0 |
The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.
| units on a scale | IR Viloxazine | Placebo |
|---|---|---|
| Raw score; Baseline | 36.0 (20 to 54) | 35.0 (21 to 45) |
| Change from Baseline score; Week 6 | -11.5 (-38 to 4) | -6.0 (-34 to 6) |
The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.
| units on a scale | IR Viloxazine | Placebo |
|---|---|---|
| Raw score; Baseline | 36.0 (20 to 54) | 35.0 (21 to 45) |
| Change from Baseline score; Week 1 | -5.0 (-29 to 1) | -2.0 (-25 to 7) |
The Global Clinical Impression-Improvement (CGI-I) scale is a single item clinician-rated assessment of how much the subject's condition (symptoms) has improved, worsened, or has not changed relative to his/her baseline state prior to the beginning of treatment; it is rated on a 7-point scale from 1 to 7, where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. The Clinical Global Impression-Severity of Illness (CGI-S) score is a single item clinician-rated assessment of the severity of subject's condition (symptoms) in relation to the clinician's total experience with patients with ADHD; it is rated on a 7-point scale with 1=Normal, not at all ill, 2=Borderline Ill, 3=Mildly Ill, 4=Moderately Ill, 5=Markedly Ill, 6=Severely Ill, 7=Among the most extremely ill patients. CGI-I scores at post-baseline visits were subtracted from CGI-S score at baseline; a change from baseline score \<0 represent better outcome.
| units on a scale | IR Viloxazine | Placebo |
|---|---|---|
| Change from "Baseline CGI-S Score"; Week 1 | 0.0 (-2 to 5) | 0.0 (-1 to 4) |
| Change from "Baseline CGI-S Score"; Week 2 | -1.0 (-2 to 5) | 0.0 (-2 to 4) |
| Change from "Baseline CGI-S Score"; Week 3 | -1.5 (-2 to 4) | 0.0 (-2 to 4) |
| Change from "Baseline CGI-S Score"; Week 4 | -1.5 (-3 to 4) | 0.0 (-2 to 5) |
| Change from "Baseline CGI-S Score"; Week 5 | -1.5 (-3 to 4) | 0.0 (-2 to 4) |
| Change from "Baseline CGI-S Score"; Week 6 | -1.0 (-3 to 4) | 0.0 (-1 to 4) |
The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.
| units on a scale | IR Viloxazine | Placebo |
|---|---|---|
| Raw Score; Baseline | 36.0 (20 to 54) | 35.0 (21 to 45) |
| Change from Baseline score; Week 2 | -8.0 (-33 to 1) | -6.0 (-27 to 6) |
| Change from Baseline score; Week 3 | -13.5 (-32 to -2) | -6.0 (-34 to 5) |
| Change from Baseline score; Week 4 | -12.5 (-33 to -3) | -7.0 (-31 to 5) |
| Change from Baseline score; Week 5 | -13.0 (-37 to 9) | -7.0 (-32 to 7) |
The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.
| units on a scale | IR Viloxazine | Placebo |
|---|---|---|
| Raw score; Baseline | 35.0 (7 to 49) | 34.0 (13 to 48) |
| Change from Baseline score; Week 6 | -10.5 (-46 to 7) | -1.0 (-35 to 8) |
The Global Clinical Impression-Improvement (CGI-I) scale is a single item clinician-rated assessment of how much the subject's condition (symptoms) has improved, worsened, or has not changed relative to his/her baseline state prior to the beginning of treatment; it is rated on a 7-point scale from 1 to 7, where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. A CGI-I score \<4 represents a better outcome.
| units on a scale | IR Viloxazine | Placebo |
|---|---|---|
| Week 1 | 5.0 (3 to 7) | 5.0 (3 to 6) |
| Week 2 | 4.0 (3 to 6) | 5.0 (2 to 6) |
| Week 3 | 3.5 (3 to 5) | 5.0 (2 to 6) |
| Week 4 | 4.0 (2 to 5) | 5.0 (2 to 6) |
| Week 5 | 4.0 (2 to 5) | 5.0 (2 to 6) |
| Week 6 | 3.5 (2 to 5) | 5.0 (2 to 6) |
Collected over Weeks 1-6 of Treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IR Viloxazine | 0/26 (0%) | 0/26 (0%) | 23/26 (88.5%) |
| Placebo | 0/25 (0%) | 0/25 (0%) | 18/25 (72%) |
| Event | IR Viloxazine | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 10/26 | 2/25 |
| HeadacheNervous system disorders | 8/26 | 9/25 |
| Decreased appetiteMetabolism and nutrition disorders | 8/26 | 1/25 |
| InsomniaPsychiatric disorders | 8/26 | 1/25 |
| Dry mouthGastrointestinal disorders | 6/26 | 3/25 |
| NasopharyngitisInfections and infestations | 0/26 | 4/25 |
| ConstipationGastrointestinal disorders | 3/26 | 2/25 |
| DyspepsiaGastrointestinal disorders | 3/26 | 0/25 |
| FatigueGeneral disorders | 3/26 | 1/25 |
| IrritabilityGeneral disorders | 3/26 | 1/25 |
Safety Population, defined as subjects who were randomly assigned to one of two treatment groups and took at least one dose of study medication
| Age, Continuous(years) | IR Viloxazine | Placebo | Total |
|---|---|---|---|
| Mean | 37.7 ± 14.04 | 43.1 ± 10.39 | 40.4 ± 12.56 |
| Sex: Female, Male(Participants) | IR Viloxazine | Placebo | Total |
|---|---|---|---|
| Female | 14 | 9 | 23 |
| Male | 12 | 16 | 28 |
| Race/Ethnicity, Customized(Participants) | IR Viloxazine | Placebo | Total |
|---|---|---|---|
| White | 24 | 24 | 48 |
| Asian | 0 | 1 | 1 |
| Other | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | IR Viloxazine | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 25 | 25 | 50 |
| Height(inches) | IR Viloxazine | Placebo | Total |
|---|---|---|---|
| Mean | 66.740 ± 3.5103 | 68.406 ± 4.0851 | 67.557 ± 3.8573 |
| Weight(pounds (lbs)) | IR Viloxazine | Placebo | Total |
|---|---|---|---|
| Mean | 163.85 ± 33.641 | 171.05 ± 33.057 | 167.38 ± 33.221 |
| BMI(kilograms per square meter) | IR Viloxazine | Placebo | Total |
|---|---|---|---|
| Mean | 25.688 ± 3.7216 | 25.664 ± 4.3620 | 25.676 ± 4.0073 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Jun 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2024, 13 years 10 months after primary completion. A results delay was requested in Dec 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity →
Supernus Pharmaceuticals, Inc. →